MaaT Pharma Announces Positive Interim Safety Results for MaaT033

MaaT Pharma has reported a positive safety interim analysis for its Phase 2b trial of MaaT033. The independent Data Safety Monitoring Board (DSMB) has suggested the study continue without changes. MaaT033, an oral drug candidate derived from pooled donors, targets patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).

The trial, named PHOEBUS, is the largest of its kind, assessing microbiome therapy in oncology. No excessive mortality linked to MaaT033 was observed after 30 patients were monitored. The trial continues to enroll patients across multiple European countries and the UK.

MaaT033's tolerability and safety profile have been confirmed, supporting its use in the allo-HSCT setting. The trial aims to enroll 387 patients in up to 60 clinical investigational sites.